AI eye examination reveals ‘cardiocerebrovascular disease’ risk: A trio aiming for global impact

• [Interview] Mediwhale CEO Kevin T. Choi, CMO Dr. Tyler H. Rim, and CPO Young G. Lee
• Opening the era of cardiovascular risk assessment and prevention with AI diagnostic program ‘DrNoon’
• Designated as a ‘statutory non-coverage for diagnostic’ product in Korea since end of 2023; Plans to apply for FDA approval in 2025

[by Lee, Young Sung] Mr. Kim, a 46-year-old man, recently had his blood pressure tested at a local hospital, where it measured 160/100, higher than normal. Using the medical AI ‘DrNoon’, he scored 43 points on the cardiovascular risk assessment, placing him in the high-risk group. With his consent, he was prescribed medication for high blood pressure.

The Korean diagnostic company ‘Mediwhale’ is pioneering the assessment and prevention of ‘cardiocerebrovascular disease’ by analyzing human retinal images with artificial intelligence (AI). The company, which began offering non-coverage diagnostics in Korea last year, aims to expand into the U.S. market, the world’s largest diagnostics market.

Mediwhale plans to seek approval from the U.S. Food and Drug Administration (FDA) for its product, ‘DrNoon Cardiovascular Risk Assessment (hereinafter referred to as DrNoon, Reti-CVD)’, in 2025.

출처 : THE BIO(https://www.thebionews.net)